Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?

There has been much debate in recent years about the difficulty in attracting both private and public funds into the UK biotech industry.  At certain points, it seemed like a disproportionate percentage of the funding that was invested into UK biotech came from the US.  It is likely that there are multiple reasons behind this, but one reason that has been put forward is that UK investors prefer a shorter timescale to exit and therefore a return on their investment.  This may be why investment in UK medtech actually appears to be flourishing; there has certainly been no shortage of private equity investment recently, with investors realising that, with medtech being much less regulated than the biotech sector, returns can be generated in a relatively short timescale.

To continue reading this article please visit Pharmafile.com.